Prospective, randomized, patient-blinded Investigator-Initiated study of DSUVIA® for patients undergoing hip or knee replacement as a same-day surgical procedure.
Latest Information Update: 02 Feb 2024
At a glance
- Drugs Sufentanil (Primary)
- Indications Perioperative pain
- Focus Therapeutic Use
- 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
- 10 May 2021 New trial record
- 06 May 2021 According to an AcelRx Pharmaceuticals media release, Dr. John Thompson is a principal investigator.